Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis

Annals of Neurology

Volumn 69, Issue 4, 2011, Pages 691-701

  Tsuji, Daisuke ^a,f   Akeboshi, Hiromi ^b,f   Matsuoka, Kazuhiko ^a,f   Yasuoka, Hiroko ^a   Miyasaki, Eri ^a   Kasahara, Yoshiko ^b   Kawashima, Ikuo ^c,f   Chiba, Yasunori ^b,f   Jigami, Yoshifumi ^b,f   Taki, Takao ^d   Sakuraba, Hitoshi ^e,f   Itoh, Kohji ^a,f  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASIALO GM2; GANGLIOSIDE GM2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MANNOSE 6 PHOSPHATE; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; RECOMBINANT BETA HEXOSAMINIDASE A; RECOMBINANT ENZYME; SPHINGOLIPID; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA HEXOSAMINIDASE A DEFICIENCY; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EPENDYMA CELL; FOREBRAIN; GENE OVEREXPRESSION; IMMUNOREACTIVITY; LIFESPAN; LYSOSOME; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NONHUMAN; OGATAEA MINUTA; PRIORITY JOURNAL; PROTEIN INDUCTION; QUALITY OF LIFE; RHOMBENCEPHALON; SANDHOFF DISEASE; TAY SACHS DISEASE; YEAST;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME REPLACEMENT THERAPY; GANGLIOSIDOSES, GM2; HEXOSAMINIDASE A; HEXOSAMINIDASE B; HUMANS; INJECTIONS, INTRAVENTRICULAR; LYSOSOMES; MANNOSE-6-PHOSPHATE ISOMERASE; MICE; MICE, KNOCKOUT; RECEPTORS, CCR1; RECOMBINANT PROTEINS; SANDHOFF DISEASE; TAY-SACHS DISEASE; TREATMENT OUTCOME; YEASTS;

EID: 79955432696     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22262     Document Type: Article

References (38)

1. Gravel RA, Kaback M, Proia, RL, et al. GM2 gangliosidoses. In:, Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3827-3876.
2. Mahuran DJ,. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta 1999; 1455: 105-138. (Pubitemid 29435983)
3. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-mediated glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
4. Sly WS, Vogler C, Grubb JH, et al. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci U S A 2006; 103: 15172-15177. (Pubitemid 44583183)
5. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16. (Pubitemid 32634266)
6. Kornfeld S, Sly W,. I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In:, Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3469-3482.
7. Grabowski GA, Kacena K, Cole JA, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type1. Genet Med 2009; 11: 92-100.
8. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α- galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000; 103: 15172-15177.
9. van den Hout, JMP, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113: 448-457.
10. Klinge L, Straub V, Neudorf U, Voit T,. Enzyme replacement therapy in classical infantile Pompe disease: results of ten-months follow-up study. Neuropediatrics 2005; 36: 6-11. (Pubitemid 41115324)
11. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study for recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144: 581-588. (Pubitemid 38594757)
12. Clarke LA, Wraith JE, Beck M, Kolodny, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123: 229-240.
13. Muenzer J, Lamsa JC, Garcia A, et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Pediatr 2002; 91: 98-99. (Pubitemid 36174159)
14. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167: 267-277.
15. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144: 574-580. (Pubitemid 38594756)
16. Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004; 83: 163-174. (Pubitemid 39328075)
17. Lee WC, Tsoi YK, Troendle FJ, et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J 2007; 21: 2520-2527. (Pubitemid 47230681)
18. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91: 61-68. (Pubitemid 46550919)
19. Chang M, Cooper JD, Sleat DE, et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2008; 16: 649-656. (Pubitemid 351426165)
20. Pastores GM,. Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opin Biol Ther 2008; 8: 1003-1009. (Pubitemid 352007010)
21. Dodge JC, Clarke J, Treleaven CM, et al. Intracerabroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 2009; 215: 349-357.
22. Akeboshi H, Chiba Y, Kasahara Y, et al. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta. Appl Environ Microbiol 2007; 73: 4805-4812. (Pubitemid 47237229)
23. Akeboshi H, Kasahara Y, Tsuji D, et al. Production of human β-hexosaminidase A with highly phosphorylated N-glycans by overexpression of the Ogataea minuta MNN4 gene. Glycobiology 2009; 19: 1002-1009.
24. Odani T, Shimma Y, Tanaka A, Jigami Y,. Cloning and analysis of the MNN4 gene required for phosphorylation of N-linked oligosaccharides in Saccharomyces cerevisiae. Glycobiology 1996; 6: 805-810. (Pubitemid 27016382)
25. Sango K, Yamanaka S, Hoffmann A, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995; 11: 170-176.
26. Sango K, McDonald MP, Crawley JN, et al. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet 1996; 14: 348-352.
27. Hemsley KM, Hopwood JJ,. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 2005; 158: 191-199. (Pubitemid 40208465)
28. Tsuji D, Kuroki A, Ishibashi Y, et al. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates. J Neurochem 2005; 92: 1497-1507. (Pubitemid 40389218)
29. Wu YP, Proia RL,. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A 2004; 101: 8425-8430. (Pubitemid 38736591)
30. Suzuki K,. Enzymatic diagnosis of sphingolipidoses. In:, Ginsbury V, ed. Methods in enzymology. New York: Academic Press, 1987; 138: 727-763.
31. Kotani M, Ozawa H, Kawashima I, et al. Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochim Biophys Acta 1992; 1117: 97-103.
32. Ozawa H, Yamashita K, Sakuraba H, et al. Generation and characterization of mouse monoclonal antibodies specific for N-linked neutral oligosaccharides of glycoproteins. Arch Biochem Biophys 1997; 342: 48-57. (Pubitemid 27217101)
33. Itakura T, Kuroki A, Ishibashi Y, et al. Inefficiency in GM2 ganglioside elimination by human lysosomal β-hexosaminidase β-subunit gene transfer fibroblast cell line derived from Sandhoff disease model mice. Biol Pharm Bull 2006; 29: 1564-1569. (Pubitemid 44166352)
34. Jeyakumar M, Norflus F, Tifft CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 2001; 7: 327-329. (Pubitemid 32061278)
35. Maegawa GH, Banwell BL, Blaser S, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab 2009; 98: 215-224.
36. Shapiro BE, Pastores GM, Gianutsos J, et al. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 2009; 11: 425-433.
37. Cachõn-González MB, Wang SZ, Lynch A, et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci U S A 2006; 5: 10373-10378. (Pubitemid 44051174)
38. Lee JP, Jeyakumar M, Gonzalez R, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 2007; 13: 439-447. (Pubitemid 46559825)